Since cancer cells possess high levels of endogenous reactive oxygen species (ROS) and are more sensitive to redox imbalance than normal cells, targeting TXNRD1 to disturb cell redox balance has been exploited as a promising strategy for cancer therapy [2,3]. The gene discussed is TXNRD1; the disease is cancer.